WINT
OQB Windtree Therapeutics, Inc.$0.0003 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0003, and at the day’s high of $0.0003
- YTD change
- -99.06%
- vs 20-day SMA
- +17.65%
- vs 200-day SMA
- -98.13%
Price ranges
Price & Performance
-0.01 (-97.41%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $275,400.0000
- WINT is down 99% since the beginning of the year
- WINT is down 100% over the past 12 months
- WINT is up 200% over the past 1 month
- 0% of all WINT investors are betting against WINT
WINT reads n/a: price sits above one of the two key moving averages, the 12-month move is -99.6%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0000
- Last 5 days
- +50.00%
- vs 8-day SMA
- +14.29%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. It's portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
